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Summary
Context: Although there are many nonsurgical therapies available for the treatment of pain associated with osteoarthritis (OA), their long-term
use and safety have not been systematically followed. Intra-articular hyaluronan therapy has been used in the treatment of symptoms
associated with OA of the knee with a very favorable safety proﬁle. Five intra-articular hyaluronan products are approved in the US. No
systematic review of the safety and efﬁcacy of their chronic use has been reported.
Objective: To evaluate the literature on the efﬁcacy and safety of repeat courses of hyaluronan therapy in patients with OA of the knee.
Data sources: MEDLINE, EMBASE, searched through October 2004.
Study selection: Databases were searched using the terms hyaluronan, sodium hyaluronate, hyaluronic acid, hylan, hylan G-F 20,
osteoarthritis, adverse events, repeat treatment, and multiple courses.
Data synthesis: There are some data that support the beneﬁt and safety of repeat treatment for all products. Data also indicate that one
formulation of sodium hyaluronate (molecular weight [MW] 500e730 kDa) is well tolerated and as effective after multiple courses of treatment
as it is after a single course. There is also clinical evidence that prolonged use of sodium hyaluronate (MW 500e730 kDa) may signiﬁcantly
decrease the rate of deterioration of joint structure. Localized severe acute inﬂammatory reactions reported with repeated treatment in some
patients are not a class effect but may be linked to physicochemical characteristics of hylan-based treatment.
Conclusions: Repeat courses of the hyaluronans are safe and effective in the treatment of pain associated with OA of the knee.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a common and debilitating condition
associated with pain and loss of mobility that undermines
patients’ quality of life (QOL). Moreover, it is estimated that
12% of the US population have clinical signs and symptoms
of this disorder1. Currently, all medications (oral, injected, or
topical) approved in the US for the treatment of OA are
indicated for the management of symptoms (pain and
limitation of function). No product is currently approved for
the treatment (slowing, halting, or reversing) of OA, and
none corrects the pathophysiologic processes that manifest
as degenerative changes in joint cartilage.
The clinical management of OA is directed at reducing
pain, maintaining or improving joint mobility, and limiting
functional impairment2. The American College of Rheuma-
tology (ACR) guidelines suggest initial nonpharmacologic
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Received 25 January 2005; revision accepted 22 April 2005.75therapy (involving patient education, physical therapy,
weight loss, exercise, unloaders, or assistive devices),
followed by various oral medications for alleviating pain as
ﬁrst-line therapy for OA2. A recent consensus conference
involving orthopedic surgeons has reiterated these recom-
mendations3. For patients with deﬁned mechanical abnor-
malities or severe OA, surgical intervention may be
indicated2.
Pharmacologic therapy initially includes simple analge-
sics, such as acetaminophen and over-the-counter non-
steroidal anti-inﬂammatory drugs (NSAIDs), and may also
include topical agents such as capsaicin cream. However,
oral NSAIDs have been associated with serious adverse
events, and a recent meta-analysis does not support their
long-term use4. In patients who fail to obtain adequate pain
relief with these more conservative interventions, cyclo-
oxygenase (COX)-2-selective inhibitors or prescription
NSAIDs with gastroprotective agents are recommended.
Some studies have suggested that COX-2 inhibitors may
reduce some of the serious adverse events associated with
NSAIDs5,6, but this remains an area of controversy, part-
icularly since the September 2004 worldwide withdrawal of
rofecoxib7. For acute ﬂares, exacerbations of pain, or
limited function, short-term opioids or intra-articular steroids1
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Most recently, the ACR guidelines have been updated to
include recommendations for use of the intra-articular
hyaluronans2.
The choice of appropriate treatment for any patient
depends on clinical history, contraindications to speciﬁc
therapies, and the overall tolerability and acceptability of the
treatment being considered. This is especially true in the
elderly, the major targeted population for OA therapy, for
whom one must consider the risk of upper gastrointestinal
or renal side effects and the diverse array of concomitant
medications used in these patients. Long-term, safe, and
effective alternatives for controlling pain and improving
function in these individuals are particularly desirable8. A
local effective therapy with a favorable safety proﬁle and no
known drug interactions would also be particularly useful for
this patient population.
Design and methodology
A review of the literature was carried out based on
a MEDLINE and EMBASE search through October 2004
using the terms hyaluronan, sodium hyaluronan, sodium
hyaluronate, hyaluronic acid, hylan, hylan G-F 20, osteoar-
thritis, adverse events, repeat treatment, and multiple
courses.
Hyaluronan in the management
of chronic OA pain
Hyaluronan is a polysaccharide found in the extracellular
matrix, particularly in soft connective tissues. This polymer
has an important role in maintaining normal joint function by
providing support and lubrication and regulating biochem-
ical processes9. In OA of the knee, both synovial ﬂuid
elastoviscosity and hyaluronan concentration are reduced,
which exposes the knee to potential physical damage10.
Intra-articular injections of high molecular weight hyaluro-
nates (O500,000 Da) were originally thought to act as ﬂuid
replacement11. It is now believed that biologic activation of
multiple protective mechanisms may explain the long-term
clinical beneﬁts12e14.
Hyaluronan products approved by the Food and Drug
Administration (FDA) and marketed in the US include
Hyalgan (sodium hyaluronate, molecular weight [MW]
500e730 kDa), Synvisc (hylan G-F 20, MW 6000 kDa),
Supartz (sodium hyaluronate, MW 630e1170 kDa), Or-
thovisc (high molecular weight hyaluronan, MW
1100e2900 kDa) and Nuﬂexxa (high molecular weight
sodium hyaluronate, MW 2400e3500 kDa)a. Sodium hya-
luronate (MW 500e730 kDa), a viscous solution of a natu-
rally derived, unmodiﬁed sodium salt of hyaluronate15, is
administered as three or ﬁve weekly 2 mL, 10-mg/mL
injections. Similarly, sodium hyaluronate (MW
630e1170 kDa), a viscous solution of a naturally derived
sodium salt of hyaluronate16, is approved as a weekly
2.5 mL, 10-mg/mL injection for 5 weeks. High molecular
weight hyaluronan (MW 1100e2900 kDa) was recently
approved and is a viscous solution administered as three
aHyalgan is a trademark of Fidia Pharmaceutical Corporation;
Synvisc is a trademark of Genzyme Biosurgery; Supartz is
a trademark of Seikagaku Corporation; Orthovisc is a trademark
of Ortho Biotech; Nuﬂexxa is a trademark of Savient Pharma-
ceuticals, Nuﬂexxa is also known as Arthrease and BioHy,
trademarks of Savient Pharmaceuticals.or four weekly 2 mL, 15-mg/mL injections. In contrast, hylan
G-F 20, a viscous solution comprising 80% hylan A (MW
6000 kDa) and 20% hylan B (a gel; indeterminate MW)
polymers17, is administered as weekly 2 mL, 8-mg/mL
injections for 3 weeks. The latest hyaluronan to be
approved in this indication, high molecular weight sodium
hyaluronate (MW 2400e3500 kDa), was approved by the
FDA in late 2004 and is prepared by a bacterial fermenta-
tion process using a proprietary non-pathogenic Strepto-
coccus zooepidemicus. It is a 1% sodium hyaluronate
solution administered as weekly 2 ml, 10-mg/mL injections
for 3 weeks. All five agents are indicated for the treatment of
pain associated with OA of the knee.
The efﬁcacy of single courses of hyaluronan in the relief
of pain and improvement in joint function has been shown in
numerous controlled clinical studies13,18e28. Wang et al.29
conducted a meta-analysis of 20 blinded randomized
controlled trials that compared the efﬁcacy of sodium
hyaluronate (MW 500e730 kDa, 630e1170 kDa or
1100e2900 kDa), or hylan G-F 20 with that of placebo in
knee OA. They found that a single course of intra-articular
sodium hyaluronate or hylan G-F 20 decreased symptoms
of OA of the knee, with signiﬁcant improvements in pain and
function with few adverse events. However, there was
signiﬁcant between-study heterogeneity in the estimates of
hyaluronan efﬁcacy. Thus, further well-designed random-
ized controlled trials with high methodologic quality are
required to determine the efﬁcacy of the different hyalur-
onan products in patients with OA of the knee.
Retreatment
Although the hyaluronans provide effective pain relief
after a single course of treatment, pain can recur in many
patients, usually after an interval of several months. Thus,
retreatment in patients who have beneﬁted from a ﬁrst
course of treatment is clinically indicated. There are
a number of points to be considered when contemplating
retreatment with a hyaluronan: (1) what patient populations
are most likely to respond to a repeat treatment, (2) the
most appropriate regimen for each patient, (3) potential for
continued or improved efﬁcacy, (4) tolerability, and (5) any
potentially beneﬁcial or detrimental effects on the un-
derlying disease processes. The discussion that follows
summarizes relevant studies for the products available in
the US and highlights issues of interest for physicians
treating patients who are candidates for hyaluronan retreat-
ment, especially as a chronic pain management modality.
SODIUM HYALURONATE (MW 500e730 kDa)
A number of clinical studies, both controlled and open-
label, have shown that retreatment with sodium hyaluronate
(MW 500e730 kDa) is both safe and effective for pain relief
in OA of the knee. These observations are reﬂected in the
removal of a precaution statement from the package insert
for sodium hyaluronate (MW 500e730 kDa) stating that the
safety and efﬁcacy of repeat treatment have not been
evaluated. Perhaps the most notable of these studies, and
the only available fully blinded, saline-controlled, and
randomized prospective assessment of a hyaluronan for
this disorder, is a recent randomized, double-blind, 1-year
comparison of sodium hyaluronate (MW 500e730 kDa) with
vehicle placebo (Table I)30. Of the 408 patients randomized
in the 17 participating UK centers, 319 completed the study,
with similar numbers of dropouts in each group; 273 were
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Studies of repeated use of sodium hyaluronate (MW 500e730 kDa) in patients with primary osteoarthritis of the knee
Regimens No. of evaluable patients Endpoints
Safety Efﬁcacy
Randomized controlled study
Double-blind placebo-controlled
trial in patients with grade II or
III primary OA of the knee;
3 courses of HA 20 mg
or placebo, three weekly
injections per course;
repeated every 4 months;
1-year follow-up30
136 patients HA;
137 patients PL
No signiﬁcant differences
in incidence and severity
of AEs with single course
or repeat treatment. The
most commonly reported
AEs were injection-site
reactions reported by
36.1% HA and 27.5%
PL patients (PZ 0.07)
Signiﬁcant improvement
from BL at 1 year in
patients with R 4.6 mm
JSW at BL with HL
compared to PL for
JSW (PZ 0.02) and
pain (PZ 0.018)
Prospective open-label studies
Conventional therapy or three
courses of HA 20 mg,
three weekly injections
per course; repeated every
3 months; 1-year follow-up32
19 patients HA;
17 patients CT
AEs were limited to
transient injection pain;
in total, 40% of patients
receiving HA reported
pain during or immediately
after the injection
Greater improvement in
QOL (P! 0.05) and
less deterioration in
knee structure
(PZ 0.016) for HA
compared with
conventional therapy
Mild to severe painful OA;
a course of ﬁve weekly
injections of HA 20 mg;
course repeated every 6 months for
2 years; 30-month follow-up14
75 patients No serious local or
systemic AEs
Spontaneous day pain
reduced by 55% from
BL (P! 0.001); overall
efﬁcacy: 48% very good,
40% good, 12% poor
Grades IIeIV severity OA;
chronic knee pain with difﬁculty on
prolonged standing and walking;
one or two courses of ﬁve
weekly injections of HA 20 mg;
24-month follow-up35
76 patients (92 knees);
13 patients (15 knees)
received a second
course
Minor and infrequent
local AEs
O50% reduction in pain
for R1 year in 72% of
patients; in the 13
retreated patients
(15 knees), 67% knees
improved after repeat
course
Grades IeIII severity OA; subjective
complaints for R 1 year, knee pain
for R20 days in month preceding
recruitment, and score of R3.3 on
10-cm VAS; a course of ﬁve weekly
injections of HA 20 mg; course
repeated after 4e8 months;
12-month follow-up36
59 patients; 14 patients
received repeat course;
six patients completed
12-month follow-up
Back pain and local injection-site
reactions most common AEs;
four joint effusions;
no serious AEs
Pain on exercise
reduced from 6.74 at
BL to 1.94 at week 52;
47% reduction; 50% of
patients ‘‘markedly
improved’’ after second
cycle at 12 months
Retrospective review
Patients received 2e8 courses of
ﬁve weekly injections of HA 20 mg38
52 patients received
R 2 courses
No recorded AEs Mean pain scores
reduced substantially
from BL to study end
MW, molecular weight; OA, osteoarthritis; HA, sodium hyaluronate (MW 500e730 kDa); PL, placebo; AEs, adverse events; BL, baseline;
JSW, joint space width; CT, conventional therapy; QOL, quality of life; VAS, visual analog scale.available for the primary analysis of joint space narrowing
(JSN). Three courses of sodium hyaluronate 20 mg or
matching placebo injections (each course consisting of one
injection every week for 3 weeks) were administered. These
courses were spaced at 4-month intervals, with the last
assessment taking place at week 52. Patients had grade II
or III primary OA of the knee according to the well-
established scoring system of Kellgren and Lawrence31.
All patients were allowed to continue their standard-of-care
NSAIDs throughout the study.
The primary study endpoint30 was joint structural change
as shown by change in radiologically determined joint
space width (JSW). A signiﬁcant effect of baseline JSW and
rate of JSN was observed, when the subgroup of patients
with a JSW R 4.6 mm at baseline, the change after 52
weeks was signiﬁcantly greater with sodium hyaluronate
than with placebo (Table I), whereas there was no
signiﬁcant difference for patients with initial JSW below4.6 mm. Although this subgroup variation may have been
attributable to a functional effect, it is also possible that the
lack of effect in patients with pronounced baseline JSN may
indicate that hyaluronans are not as effective on cartilage
that is severely damaged prior to starting therapy. The
effect of repeated courses of sodium hyaluronate was also
observed in terms of incremental improvement in pain on
walking as assessed by visual analog scale (VAS).
Statistically signiﬁcantly incremental improved pain relief
above that of standard-of-care NSAIDs was obtained with
active treatment compared to saline-control injections at
weeks 11, 35, and 52, all of which tended to be 3e4 months
following a course of intra-articular injections. These results
indicate the provision of sustained pain relief by the series
of courses used. Categorical pain assessment on a six-
point scale also showed improvement with active treatment
relative to placebo at week 11 (42.2% vs 35.5% rated pain
as ‘‘improved’’; PZ 0.04) and week 35 (44.2% vs 32.7%;
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statistically signiﬁcant at these time points. Again, it should
be noted that this represents an incremental improvement
above oral pain medications as the patients continued to
have free access to their usual antiarthritic medication
(NSAIDs or analgesics) throughout the study. In addition,
because intra-articular injection involves aspiration of the
knee joint, this is likely to have enhanced placebo
responses30.
As might be expected, most of the reported adverse
events were localized to the treated joint, and the most
common adverse events were injection-site reactions,
reported by 36.1% of sodium hyaluronate and 27.5% of
placebo recipients (PZ 0.07). Overall, although at least
one adverse event was reported in 89.9% and 84% of
patients in the sodium hyaluronate and placebo groups,
respectively (PZ 0.079), there was no signiﬁcant increase
in intensity or frequency of adverse events reported with
repeat treatment30.
A small open-label, standard-of-care-controlled (i.e., no
intra-articular therapy), prospective comparison of sodium
hyaluronate (MW 500e730 kDa) with conventional therapy
has also been carried out in 39 patients, 36 of whom
completed three courses of three injections (courses at 3-
month intervals) with a 12-month follow-up (Table I)32. All
patients underwent knee arthroscopy with lavage at
baseline. The primary endpoint was progression of de-
generative change in cartilage as assessed by blinded
arthroscopy. After 12 months, chondropathy (as assessed
by 100-mm VAS on arthroscopy) was signiﬁcantly
(PZ 0.016) less severe in the sodium hyaluronate group
than in the conventional therapy group (Table I). Between-
group comparison for changes in clinical parameters
reached statistical signiﬁcance for the QOL index (Arthritis
Impact Measurement Scale 2 [AIMS-2])33. Improvement in
OA pain (VAS) and function was not signiﬁcantly different
between groups. QOL was also assessed in this study and
improved signiﬁcantly in the sodium hyaluronate group
compared with the control group. (This is discussed in more
detail later in this review.) In addition, signiﬁcantly fewer
patients in the sodium hyaluronate group used NSAIDs
(30% vs 68.4%, respectively; PZ 0.016). The most
common adverse event related to sodium hyaluronate
was transient injection pain. No acute hydrarthrodial ﬂares
of OA occurred. There were no signiﬁcant differences
between groups in terms of the Lequesne index of
functional impairment34 in this study.
Other prospective studies of repeated courses of sodium
hyaluronate (MW 500e730 kDa) have been noncompara-
tive, open-label assessments covering follow-up periods of
12e30 months (Table I). One of these studies14 focused on
repeat treatment, whereas others involved small propor-
tions of patients who had received a repeat course after
initial treatment and assessment35,36. In all of these trials,
patients with OA of the knee received ﬁve weekly intra-
articular injections of sodium hyaluronate (MW
500e730 kDa) (20 mg in 2 mL) per course. In the repeat-
treatment study of Scali14, this regimen was repeated in all
75 patients at 6-month intervals for 2 years (irrespective of
symptom status), with a ﬁnal evaluation at 30 months
(Table I). As a result, each patient had received a total of 25
injections (approximately 1875 injections in total), and all
patients completed the study. Scali14 measured spontane-
ous day pain (primary endpoint), which decreased signiﬁ-
cantly 6 months after the ﬁrst treatment course and
continued to decrease until study end, as measured by
the Huskisson 100-mm VAS37. Morning stiffness and otherpain parameters, such as pain at night, at rest, on touch,
and on movement, also declined substantially after the ﬁrst
treatment course and continued to do so for the duration of
the study. At study end, 29% (22/75) of patients were free
from night pain, 21% (16/75) from pain at rest, 19% (14/75)
from pain on touch, and 8% (6/75) from pain on movement.
Statistical signiﬁcance for change from baseline was
attained for night pain and for spontaneous day pain at
rest (P! 0.001). Joint ﬂexion and extension improved
signiﬁcantly after the ﬁrst treatment cycle and, along with
suprapatellar circumference, was signiﬁcantly improved at
the end of the study relative to baseline. Furthermore,
signiﬁcantly fewer patients had joint effusion at study end
(7%) than at baseline (47%), and the percentage of patients
using acetaminophen decreased from 40% at baseline to
5% at study end. By the end of the study, overall
improvement was judged as ‘‘good’’ or ‘‘very good’’ in
88% of patients which represented an increase over the
60% noted after the ﬁrst cycle of treatment (P! 0.05 for
both vs baseline). Five patients reported transient injection-
site pain, but no serious local or systemic adverse events
were observed after repeat treatment.
Noncomparative studies also indicate clinical improve-
ment after second treatment courses of sodium hyaluronate
(MW 500e730 kDa) (Table I). Of 108 enrolled patients in
one of these trials36, 59 were evaluated after 12 months.
Fourteen of the patients who had responded but whose
pain had returned within 12 months received a second
treatment cycle after the loss of an initial 4- to 8-month
beneﬁt. Of patients who received a second course of
therapy, 50% had an improvement in symptoms that lasted
an additional 12 months after repeat treatment. Although
numbers of patients were very small, these data suggest
that repeat treatment may increase duration of efﬁcacy
beyond that seen with a ﬁrst course and may be delivered
as pain returns or as needed rather than on a deﬁned
schedule. Overall, 119 adverse events were reported in 108
patients; the most common were back pain (16.8%),
injection-site reaction (11.8%), and injection-site pain
(6.7%). Four instances of joint effusion were observed,
but it was not stated whether these were seen with the ﬁrst
or second course of injections.
Another noncomparative study in 76 patients (92 knees
treated) who were followed up for 24 months showed a high
rate of clinical improvement in 13 individuals (15 knees
treated) who were treated with a second course of ﬁve
injections for either inadequate initial response or early
recurrence of pain (Table I) and followed for 6 weeks35. No
serious adverse events were noted.
A retrospective survey of 52 patients who received 2e8
course of intra-articular sodium hyaluronate (MW
500e730 kDa) 20 mg once weekly for 5 weeks is also
available for analysis (Table I)38. All 52 patients received at
least two cycles of treatment. Mean VAS pain scores for
spontaneous and forced movement were reduced sub-
stantially from the beginning of cycle 1 to its end, and again
from the beginning to the end of cycle 2 (Fig. 1). A mean
11.2 months (range 3e27) elapsed between the ﬁrst two
cycles.
A retrospective review of 166 charts from patients who
had received multiple courses of intra-articular hyaluronan
therapy between September 1, 1997 and September 15,
2002 (representing approximately 2800 intra-articular in-
jections), was conducted by Hamburger et al.39. All patients
received at least one repeat treatment course, and
approximately 30% of patients received three or more
courses of sodium hyaluronate (MW 500e730 kDa) or
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retreated with sodium hyaluronate, and 24 patients (43
knees) were retreated with hylan G-F 20. Among the
patients treated with hylan G-F 20, 16.3% reported a severe
acute inﬂammatory reaction (SAIR) resembling a septic
joint and requiring additional clinical intervention. No such
reactions were reported with sodium hyaluronate (Table II).
Similarly, Garcia40 conducted a comparative safety and
efﬁcacy study in 61 patients randomly administered three
weekly injections of hylan G-F 20 or ﬁve weekly injections of
sodium hyaluronate (MW 500e730 kDa) (Table II). Al-
though no statistical difference was noted in improvement
from baseline for the two groups, 10.3% of the patients
injected with hylan G-F 20 reported pseudoseptic reactions,
but none of the patients injected with sodium hyaluronate
reported such reactions (Table II). All of the reactions
occurred after the second or third injection, seemingly
requiring sensitization.
HYLAN G-F 20
There are no prospective and controlled studies re-
garding the efﬁcacy and safety of hylan G-F 20 in the
retreatment setting. However, the labeling was changed in
Fig. 1. Visual analog scale (VAS) pain scores (0e100) after two
courses of ﬁve weekly injections of sodium hyaluronate (MW
500e730 kDa) in a retrospective survey of 52 patients with
osteoarthritis of the knee38. All patients had followed a standard
assessment protocol, and the mean interval between cycles 1 and
2 was 11.2 months.December 2003 with the removal of a precaution statement
from the package insert for hylan G-F 20 stating that the
safety and efﬁcacy of repeat treatment have not been
established. The three available studies include a prospec-
tive, open-label study of patients treated with a second
course of hylan G-F 2041, a Canadian retrospective
postmarketing study of all patients with OA of the knee
receiving hylan G-F 20 treatment over a period of 2.5 years
(includes details of repeat treatment)42, and a retrospective
database analysis of patients receiving more than one
course of treatment43 (Table III).
The open-label study enrolled patients who had pre-
viously received clinical beneﬁt from an initial course of
hylan G-F 20 but requested a second course because of
return of OA knee pain41 (Table III). Seventy-one patients
received up to three weekly injections in the second course
and were followed for 26 weeks. The second course of
hylan G-F 20 signiﬁcantly reduced pain while walking on
a ﬂat surface at weeks 1, 2, 4, 8, 12, and 26, compared
to baseline (P! 0.001). Signiﬁcant improvements from
baseline were also seen at all time points for physical
function, as measured by scores for the Western Ontario
and McMaster Universities Arthritis Criteria (WOMAC)
domain C and full WOMAC, and patient and investigator
overall pain scores as measured by VAS (P! 0.001).
Of the 54 patients who experienced at least one adverse
event, three had events possibly related to treatment, three
had events probably related to treatment, and seven had
events deﬁnitely related to treatment. This reﬂected a rate of
related adverse events per injection of 6%. Most of these
hylan G-F 20-related adverse events were mild to moderate
in severity, with only one patient experiencing a severe
case of arthrosis.
In the Canadian analysis, 336 patients (458 knees)
received three consecutive weekly 2 mL intra-articular
injections of hylan G-F 20; up to four courses over a 2.5-
year period42 (Table III). Bilateral treatment was given to
112 patients in the ﬁrst course; 15 were treated bilaterally in
the second course, and four patients received third and
fourth courses (all unilateral). In 56 knees that received two
courses (mean, 8.2 months apart), overall response was
considered ‘‘better’’ or ‘‘much better’’ on a ﬁve-point ordinal
scale in 87% of these cases, which compared with a rate of
77% after the ﬁrst course. Similarly, activity level was
judged as ‘‘better’’ or ‘‘much better’’ in 84% of knees after
two courses, which was compared with a rate of 76% after
the ﬁrst course. Differences between ﬁrst and secondTable II
Comparative studies of repeated use of sodium hyaluronate (MW 500e730 kDa) or hylan G-F 20 in patients with primary osteoarthritis of the
knee
Regimens No. of evaluable patients Endpoints
Safety Efﬁcacy
Retrospective review
Patients received at
least two courses of
HA or hylan G-F 2039
166 patients (2800 injections):
142 HA 24 hylan G-F 20
SAIR reported in 16.3%
of hylan G-F 20 patients
and none of the HA patients
Not reported
Open-label study
Patients were randomized
to a course of HA, ﬁve
weekly injections per course,
or hylan G-F 20, three weekly
injections per course40
61 patients Pseudoseptic reactions
reported in 10.3% of hylan
G-F 20 patients and none
of the HA patients
No signiﬁcant difference
in improvement from BL
between the two groups
HA, sodium hyaluronate (MW 500e730 kDa); SAIR, severe acute inﬂammatory reaction; BL, baseline.
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Studies of repeated use of hylan G-F 20 in patients with primary osteoarthritis of the knee
Regimens No. of evaluable patients Endpoints
Safety Efﬁcacy
Patients received up to
four courses of hylan
G-F 20, three weekly
injections per course;
treatment period 2.5 years42
336 patients
(1537 injections, 458 knees)
Local AEs in
28 patients (8.3%);
no systemic AEs;
72% of AEs deemed
injection related
Overall response in 77%
of patients after one injection
and 87% after two injections
(not statistically signiﬁcant)
Patients received hylan
G-F 20, three weekly
injections per course;
single or multiple courses43;
patients receiving a single
course of hylan G-F 20 as
part of a randomized study
comparing HA with corticosteroid
injections were compared with
patients receiving O1 course,
identiﬁed by a retrospective
chart review
19 patients multiple courses;
42 patients single course
Frequency of acute
local reactions 10!
greater in multiple-course
patients compared with
single-course patients (PZ 0.029)
Resolution of symptoms in
all patients
Two courses of hylan G-F 20,
three weekly injections per course;
second course administered after
3 months44
22 patients
(88 injections, 28 knees)
Unpredictable occurrence of
acute reactions; six patients
had acute local reactions
starting within 24 h and lasting
up to 3 weeks
Not reported
Patients received at least two
courses of hylan G-F 20, three
weekly injections per course45
Eight patients No reactions on ﬁrst injection in
any patients; local reactions in
two patients after second injection,
in four patients after third injection,
and in four patients during
second course
Favorable response
(no details given)
All patients had previously
received one course of hylan
G-F 20; patients received a second
course of hylan G-F 20 (up to three
consecutive weekly injections);
mean time between ﬁrst and second
course was 19.6 months. Patients
were followed for 26 weeks after the
ﬁrst injection of the second course.41
71 patients Second course was well tolerated
with low incidence of local AEs;
severe AE in one patient (arthrosis);
no patient discontinued due to AEs
Pain reduced signiﬁcantly
from BL (P! 0.001)
Case review of patients requiring
surgery due to persistent symptoms
after receiving one course of hylan
G-F 20; three weekly injections46
Five patients
(six knees)
Granulomatous inﬂammation and
synovitis seen in all patients deemed
to be a direct result of hylan G-F 20
injections; two other patients having
surgery who had not received hylan
G-F 20 did not show evidence of
granulomatous inﬂammation
Persistent symptoms in
all patients
AEs, adverse events; HA, sodium hyaluronate (MW 500e730 kDa); BL, baseline.courses were not statistically signiﬁcant, although it should
be noted that the number of knees treated with a second
course was much smaller than the ﬁrst. Duration of beneﬁt
was considered similar after each cycle. Improvement in
efﬁcacy following the third and fourth courses was similar to
that seen after the ﬁrst two cycles. After the second course,
approximately half of the 31 patients involved were able to
reduce their use of analgesics (49%) and NSAIDs (52%),
which was similar to the pattern noted after the ﬁrst course
of therapy42.
No systemic adverse events were observed in the above
study, and incidences of local adverse events (approxi-
mately 3% of injections) did not differ signiﬁcantly for ﬁrst or
second courses. However, this result contrasts with the
other available analysis, which focused on localized
adverse reactions to hylan G-F 20 treatment. Leopold and
colleagues43 reported a 10-fold increase in the frequency of
acute local reactions in 19 patients treated with multiplecourses of hylan G-F 20 (four patients; 21.1%) when
compared with the frequency in 42 patients who received
only one course (one patient; 2.4%) (Table III). In this
analysis, 15 patients had received two courses and four
patients had received three courses. Puttick et al.44
assessed localized reactions to intra-articular hylan G-F
20 and concluded that acute reactions were difﬁcult to
predict, with patients tolerating between one and four
injections before the onset of a reaction (Table III). Similarly,
Pullman-Mooar et al.45 reported that four of 10 reactions
were noted during second or third courses in a very small
retrospectively studied sample (eight patients) (Table III).
In a case review of ﬁve patients requiring surgery
because of persistent symptoms after receiving a course
of three weekly injections of hylan G-F 2046, the granulo-
matous inﬂammation observed in each patient was deemed
to be a direct result of viscosupplementation therapy (Table
III). Chen et al.46 reported that two additional patients
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did not show evidence of a granulomatous inﬂammation
reaction, suggesting that the reactions seen in the ﬁve
patients receiving injections were due to viscosupplemen-
tation therapy. However, Waddell notes that as stated in the
hylan G-F 20 package insert, patients with more severe
disease may be more susceptible to local adverse events
than are patients with less severe disease47. Thus, the
reason for a higher likelihood of adverse events with
repeated hylan G-F 20 therapy may be because patients
with more severe disease are more likely to receive
repeated courses of therapy than are patients with less
severe disease.
The only available assessment for sodium hyaluronate
(MW 630e1170 kDa) that includes retreated patients is
a postmarketing analysis of 8830 patients (7262 having OA
of the knee) receiving from one to more than 50 injections
over a 6-year period48. Although several patients were
treated for more than 1 year, including a patient treated for 4
years and 5 months who received 139 injections, the exact
number of treatment courses was not reported. ‘‘Good’’ or
‘‘excellent’’ improvement was observed in 63e66% of
patients who received one or two injections, 68e76% of
patients who received three to 19 injections, and 53e63%
of patients who received more than 19 injections. Adverse
events were reported spontaneously (further details not
given) by 0.5% of patients, with the most common being
injection-site pain, but incidence could not be related to
treatment course based on the information presented.
Interestingly, no adverse events were seen in patients
treated for more than 1 year. The limitations of this analysis
in terms of scope, design, and detail make meaningful
interpretation and comparison of single and multiple
courses impossible.
The package insert for sodium hyaluronate (MW
630e1170 kDa) contains a precaution statement that the
safety and efﬁcacy of repeat treatment have not been
established.
HIGH MOLECULAR WEIGHT HYALURONAN
(MW 1100e2900 kDa)
Although high molecular weight hyaluronan received
a CE Mark approval in Europe in 1996 and has been
marketed in several nations in Europe and the Middle East,
as well as in Canada since 1998, we were unable to ﬁnd
any data to support or refute its use in repeat treatment
courses. As with sodium hyaluronate (MW 630e1170 kDa),
the FDA-approved labeling for high molecular weight
hyaluronan (MW 1100e2900 kDa) contains a precaution
statement that the safety and effectiveness of repeat
treatment have not been established.
Localized inﬂammatory reactions
and pseudosepsis
As has been described earlier, although the class has
a very favorable safety proﬁle with no known drug
interactions, there is an adverse event of some concern
with hyaluronan treatment with the cross-linked form of
hyaluronan, hylan. Published reports describe SAIR49 or
pseudoseptic reaction, only in response to the derivatized
hylan G-F 20. Published data to date have not revealed any
evidence of increased incidence of adverse events with
repeated courses of naturally extracted hyaluronans (sodium
hyaluronate [MW 500e730 kDa or 630e1170 kDa] or high
molecular weight hyaluronan). In a prospective, single-blind,randomized study of patients with knee OA receiving
three or ﬁve weekly injections of sodium hyaluronate (MW
500e730 kDa) (nZ 36, 180 injections) or hylan G-F 20
(nZ 38, 114 injections), no patients in the sodium
hyaluronate group developed pseudoseptic reactions,
compared with two of 38 (5.3%) patients in the hylan
G-F 20 group50. Michou et al. reported two cases of
inﬂammatory knee arthritis after intra-articular injection of
hylan G-F 20d2 days after the second injection in one
patient and 3 days after the third injection in the other
patient51. Histology revealed granulomatous synovitis free
of organisms and crystals. Even though hylan G-F 20
labeling was changed in December 2003 and the
precaution statement that the safety and efﬁcacy of
repeat treatment have not been established was elimi-
nated, new language in the package insert clearly points
to this reaction as being well documented with this
product. This is especially true in light of data reported by
Leopold et al.43. Of further concern is the possible
sequelae that may lead to the development of chronic
granulomatous reactions and require signiﬁcant clinical
intervention46,52. Although there has been no direct link
between SAIRs and chronic granulomatous reactions,
a common immunologic basis for their occurrence has
been postulated. Furthermore, a preclinical study in
rabbits and guinea pigs has demonstrated that only hylan
G-F 20, and not sodium hyaluronate (MW 630e1170 kDa)
or sodium hyaluronate (MW 500e730 kDa), elicited
immunologic and granulomatous reactions53,54.
The reader is referred to a recently published compre-
hensive review that addresses the challenges of diagnosing
and treating pseudoseptic reactions to hylan G-F 2055. A
variety of mechanisms underlying acute local reactions to
hyaluronans have been postulated, including immune-
mediated responses44, direct stimulation of inﬂammatory
mediators or leukocyte migration56,57, induction of calcium
pyrophosphate dihydrate arthritis56,58,59, blocking of synovial
outﬂow60, and tissue irritation related to inadvertent para-
articular injection60e62. The lack of clinical or laboratory
evidence of infection in Leopold and colleagues’ patients
suggests a so-called pseudoseptic (or severe acute
inﬂammatory) reaction as described and also discussed
in a recent review of the safety of the hyaluronan class by
Hamburger et al.39. Published data support a difference in
clinical tolerability between cross-linked hylan G-F 20 and
naturally derived hyaluronate. Several clinical reports have
been published which report reactions to hylan G-F 2063e65.
Pseudosepsis has not been described in patients re-
ceiving sodium hyaluronate66. A study comparing hylan G-F
20 with sodium hyaluronate showed no pseudoseptic
reactions with hyaluronate67. Animal data also suggest
product-speciﬁc differences between these agents and
hylan G-F 2068,69. Indeed, there is a case report of patients
having an SAIR to hylan G-F 20 and subsequently being
retreated with sodium hyaluronate (MW 500e730 kDa) with
a good clinical outcome and without further sequelae70.
This was also shown in a prospective, randomized clinical
practice study comparing hylan G-F20 and sodium hyalur-
onate (500e730 kDa)40. Although pseudoseptic reactions
cannot be ruled out with naturally derived hyaluronans71, if
they do occur, it would appear to be at a very much lower
frequency than with crosslinked hylan66. However, lack of
evidence from suitably designed studies precludes deﬁnitive
comparative conclusions at present, Leopold et al.43 ad-
vised counseling of patients with respect to potential
adverse events before administration of second courses of
hylan G-F 20.
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Patients with OA of the knee can have substantially
impaired mobility and pain, which can affect social
functioning, psychological status, and the ability to carry
out activities of daily living72. Several studies have shown
QOL improvements with single courses of sodium hyalur-
onate (MW 500e730 kDa) and have suggested that
treatment may delay the need for total knee replacement
and also decrease clinical management costs73,74. Similarly,
a single course of hylan G-F 20 has been reported to
improve patient well-being, including physical, social, and
role aspects of function75.
Studies assessing QOL after retreatment are limited, and
there are no comparisons of repeat therapy with single
courses. However, one of the saline-controlled studies of
sodium hyaluronate (MW 500e730 kDa) reviewed above
included an assessment of QOL in retreated patients32.
Listrat and colleagues33 used the 12-item AIMS-2 in their
comparison of three cycles of sodium hyaluronate (MW
500e730 kDa) (three weekly injections every 3 months) and
routine therapy without intra-articular treatment. Sodium
hyaluronate signiﬁcantly improved overall QOL at 1 year,
whereas QOL deteriorated in the group not receiving
intra-articular treatment. These ﬁndings accompanied the
demonstration of less chondropathy in the sodium hyalur-
onate-treated group as discussed earlier in this review.
QOL was also assessed in the double-blind placebo-
controlled study of Jubb et al.30, who found no statistically
signiﬁcant difference between groups in overall 36-Item
Short-Form (SF) Health Survey76 questionnaire scores, but
who did record an advantage for sodium hyaluronate (MW
500e730 kDa) in terms of the vitality subscale (PZ 0.03).
Economically, the cost of hyaluronan therapy might be
offset by clinical beneﬁts such as reductions in number of
physician visits, reduced need for or delayed surgery, and
reduced use of other medications. A German study
comparing standard therapy alone (89 patients) with
standard therapy plus sodium hyaluronate (MW
500e730 kDa) (90 patients) showed a cost-effectiveness
advantage for sodium hyaluronate that was related to
reduced use of medications and their associated side
effects with substantial improvements in QOL74. Beneﬁt, as
shown by reduced pain intensity and the EuroQOL scale (a
standardized instrument used in conjunction with disease-
speciﬁc tools as a measure of health outcomes), was
combined with a cost analysis that captured a wide variety
of direct (e.g., physician, medication, surgery) and disability
costs. The incremental cost-effectiveness of sodium hya-
luronate when all costs were considered varied according to
the QOL tool applied, but was below 200 DM per index or
scale unit per patient for pain intensity, EuroQOL scale, and
Lequesne index. It was not clear whether any of the patients
analyzed were under repeat treatment, and the perspective
of the study and year of costing were not speciﬁed;
nevertheless, the results suggest that the clinical beneﬁt
of sodium hyaluronate (MW 500e730 kDa) therapy may
offset additional costs.
This concept has been examined in more detail in
a prospective, randomized, open 1-year Canadian study.
This study, conducted in 255 patients, compared hylan G-F
20 plus ‘‘appropriate care’’ with appropriate care alone and
found that the incremental costeutility ratio for hylan G-F 20
was Can$10,000 (1999 values) per quality-adjusted life-
year (QALY). The analysis, which was well designed and
used mean WOMAC score as the primary QOL outcome,
was carried out from a societal perspective and capturedboth direct and indirect costs. Most importantly, patients
undergoing repeat treatment were also included in the
sample, although the proportion represented was not
speciﬁed. The cost per QALY was shown to be robust by
sensitivity analysis and was below the suggested (1992)
Canadian adoption threshold of Can$20,000 per QALY77. In
addition, the costeutility ratio for hylan G-F 20 therapy was
more favorable than an estimate (in 1998 US dollars) for
misoprostol prophylaxis in patients with rheumatoid arthritis
taking NSAIDs ($US11,000 for patients older than 60
years)78.
In a prospective, randomized study of 506 patients given
hylan G-F 20 or conventional treatment for OA of the knee,
the costs over a 9-month period to the French public health
insurance system were evaluated79. Clinical status was
evaluated using the Lequesne index, the WOMAC index,
and the SF-12 QOL questionnaire. In addition, medical and
sick leave costs were determined. Signiﬁcant clinical
improvements were noted from months 1e9 of the study
in the hylan G-F 20 group. A mean two-point difference in
the Lequesne index area under the curve was found in favor
of hylan G-F 20 (P! 0.0001). There was no difference in
disability measures between groups. This study conﬁrmed
that hylan G-F 20 was more effective than was conventional
treatment, at no additional cost.
Hyaluronan as a treatment option in the
management of chronic knee pain
The range of practical options for the management of
chronic pain associated with OA of the knee is limited. In
addition, many patients requiring pharmacologic interven-
tion for symptomatic relief of OA are elderly. These patients
often have comorbidities that require multiple concomitant
medications and can be especially susceptible to the
gastrointestinal adverse effects associated with NSAIDs. A
caseecontrol study of 1415 Medicaid patients 65 years
of age or older estimated a relative risk for development of
peptic ulceration of 4.1 in users of these drugs, with 29%
of ulcers in the sample resulting from NSAID use and an
excess risk of 17.4 hospitalizations for ulceration per 1000
patient-years of exposure80. Indeed, a recent meta-analysis
does not support the long-term use of oral NSAIDs in knee
OA4. The analysis included 23 randomized placebo-
controlled trials of 10,845 patients (median age, 62.5 years)
treated with NSAIDs (including COX-2 inhibitors) or placebo.
NSAIDs reduced short-term pain slightly more than
placebo did, but because of the serious gastrointestinal
and cardiovascular adverse effects associated with these
drugs, long-term use could not be recommended.
Furthermore, although COX-2-selective inhibitors carry
a signiﬁcantly reduced risk relative to NSAIDs5,6, gastro-
intestinal adverse events are not completely eliminated,
and questions concerning the cardiovascular tolerability of
these agents have been raised81. Of particular concern is
the September 2004 worldwide withdrawal of rofecoxib,
which has cast doubt on the entire COX-2 inhibitor class7.
The withdrawal resulted from the high rate of cardiovas-
cular adverse events during a 3-year colon polyp
prevention study; myocardial infarctions and strokes
occurred in a much higher proportion of the 1300
volunteers taking rofecoxib (3.5%) than the 1300 volun-
teers taking placebo (1.9%)7. Questions remain as to
whether this effect is unique to rofecoxib or is a class
effect. The potential for serious gastrointestinal and
cardiovascular adverse events may be reduced with the
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onans.
The effectiveness of NSAIDs for long-term management
is also called into question by the observation that very high
proportions of patients with OA do not remain on the same
analgesic prescription for extended periods82. In addition,
the generally accepted tendency for elderly patients to use
multiple medications increases the potential for drug
interactions in this patient population. Localized therapies,
such as intra-articular treatments, are therefore an attractive
treatment option in these patients, and it should be
reiterated that recommendations for intra-articular hyalur-
onan use have now been integrated into the ACR guide-
lines for the management of OA of the knee2.
Irrespective of the tolerance or acceptability of oral pain
medications for OA of the knee, none of the symptom-
relieving medications has been shown to have a positive
impact on the disease of OA. Indeed, there is evidence to
suggest that some NSAIDs may actually have a negative
impact on OA progression. Therefore, the fact that there is
signiﬁcant supportive evidence for at least one hyaluronan
(sodium hyaluronate, MW 500e730 kDa) having a positive
effect on cartilage matrix preservation adds to the notion
that this therapeutic modality beneﬁts patients with OA.
The five hyaluronan products available in the US are all
highly puriﬁed and meet quality standards required by the
FDA, but they are, nevertheless, distinguishable on the
basis of clinical support, dosing and injection regimens,
labeling, and manufacturing processes. Two of the products
(sodium hyaluronate, MW 500e730 kDa and hylan G-F 20)
have had removal of a precaution statement from the
package insert that stated the safety and efﬁcacy of repeat
treatment have not been established, but sodium hyaluro-
nate, MW 620e1170 kDa and high molecular weight
hyaluronan continue to have such limitations on their
approved use. Four of the five approved products are
derived from rooster combs and one is a fermented product.
One of the avian derived products is further processed and
chemically cross-linked to increase its molecular weight17.
Recent data suggest that this may have tolerability
implications, as previously discussed in this review. Thus,
the hyaluronans have been shown overall to be safe and
effective in the treatment of pain associated with OA of the
knee, and repeat treatment is recommended when data and
labeling support such use. Furthermore, initial pharmacoe-
conomic data suggest that hyaluronan therapy can be very
cost-effective compared to most standard-of-care treat-
ments, and the potential disease-modifying properties of
one product (sodium hyaluronate, MW 500e730 kDa) need
to be fully considered in choosing an appropriate therapy for
patients with OA knee pain.
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